For roughly three years, compounded semaglutide and tirzepatide occupied a legally ambiguous but practically tolerated corner of obesity medicine — filling real access gaps during genuine national shortages, and simultaneously enabling a parallel ecosystem of telehealth weight loss clinics operating with little clinical oversight. That era is now formally closed.
Both medications have been removed from the FDA's drug shortage list. Enforcement discretion periods have expired. Court challenges from compounders have been denied. And providers who continue to prescribe compounded versions — or who have patients currently on them — are navigating a regulatory and liability landscape that has changed substantially. This article covers what you need to know clinically, legally, and practically right now.
Why compounding was allowed in the first place
Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are generally prohibited from producing drugs that are essentially copies of commercially available FDA-approved products. The key exception: when a drug is listed on the FDA's official Drug Shortage List, this restriction is lifted. Compounders can legally produce copies of shortage-listed drugs to help meet unmet patient demand.
Both semaglutide and tirzepatide were placed on the shortage list as demand dramatically outpaced manufacturing capacity during 2022–2024. The shortage was real. Patients who had prescriptions for Ozempic, Wegovy, Mounjaro, and Zepbound genuinely could not fill them in many markets. Compounding was a legally available bridge — and for many patients, the only accessible option.
503A pharmacies (state-licensed traditional compounding pharmacies) can compound shortage-listed drugs for individual patients with a valid prescription. They are not required to follow Current Good Manufacturing Practice (cGMP) requirements and do not submit adverse events to the FDA.
503B outsourcing facilities (FDA-registered, higher-oversight facilities) can compound shortage-listed drugs in bulk — including for distribution to clinics and hospitals without patient-specific prescriptions. They are subject to cGMP requirements and FDA inspection, and must submit adverse event reports.
Once a drug is removed from the shortage list, the legal basis for compounding essentially a copy of it evaporates — with very narrow exceptions for documented patient-specific clinical need.
FDA enforcement timeline
What's actually in compounded versions vs. brand
The clinical and safety picture of compounded GLP-1 medications is substantially more complicated than "same drug, lower price." Understanding the specific differences is essential for counseling patients and assessing risk.
The active ingredient problem
FDA-approved semaglutide (Ozempic, Wegovy) contains semaglutide as the active ingredient — the specific molecular form tested in clinical trials. Some compounded "semaglutide" products have used semaglutide sodium or semaglutide acetate — salt forms that are chemically different from the approved active ingredient. The FDA has explicitly stated it has no information on whether these salts have the same pharmacological properties as approved semaglutide, and there is no lawful basis for their use in compounding. Patients taking these products are not, in any meaningful clinical sense, taking the medication they believe they are taking.
Formulation and concentration variability
Brand semaglutide and tirzepatide come in pre-filled autoinjector pens with standardized, fixed concentrations and pre-set doses. Patients inject a fixed amount and are done. Compounded versions were typically dispensed in multi-dose vials at concentrations that varied between compounders — and sometimes between batches from the same compounder. Patients had to draw up their own dose using a syringe, converting between milligrams, milliliters, and sometimes "units" — a measurement whose volume depends on concentration. This is the mechanism behind the 5–20× overdose events the FDA documented.
Add-on ingredients — and why 80% of compounded prescriptions now include them
Many compounded formulations include additional active pharmaceutical ingredients — most commonly B vitamins (B6, B12) and L-carnitine, marketed as offering additional metabolic benefits. There is no clinical trial evidence that these additions improve outcomes. Their safety in combination with GLP-1 agents has not been studied. But there is a more significant reason this practice has accelerated: IQVIA data from October 2025 showed that approximately 80% of compounded semaglutide and tirzepatide prescriptions now contain add-on ingredients — largely as a legal strategy to avoid the "essentially copy" classification that would make the product an illegal copy of an approved drug. Eli Lilly has warned about potential impurity risks from compounds that use this approach.
Clinical and safety concerns
🚨 The documented safety concerns with compounded GLP-1 products
- Dosing errors: As of April 30, 2025, the FDA had received 520 adverse event reports for compounded semaglutide and 480 for compounded tirzepatide — with actual numbers believed to be substantially higher due to 503A pharmacies not being required to report. Reported events include nausea, vomiting, pancreatitis, gallstones, fainting, dehydration, and hospitalization.
- Death reports: As of December 31, 2024, 17 deaths had been entered in FAERS associated with compounded semaglutide and tirzepatide — representing more than four times the adverse event count for all compounded drugs in FY2022.
- Unverified active ingredients: Salt forms (semaglutide sodium, semaglutide acetate) used in some formulations are not the same molecule as approved semaglutide and have not been evaluated for safety or efficacy.
- No FDA quality review: 503A pharmacies are not subject to cGMP requirements. An April 2025 Brookings Institution report found that three Chinese firms responsible for 20% of compounded semaglutide API imports had never been FDA-inspected; three others accounting for 44% of imports had active violations. Novo Nordisk's own testing of compounded injectable semaglutide found impurities as high as 86% in some samples — raising serious concerns for immunogenicity and anaphylaxis risk.
- Counterfeit products: FDA has identified fraudulent compounded products with false pharmacy labels — including cases where the named pharmacy did not actually compound the product. Counterfeit GLP-1 products are actively circulating online and through direct-to-consumer channels.
- Off-label dosing regimens: Multiple reports of patients being prescribed higher starting doses, more frequent dosing, or faster titration than FDA-approved labeling — compounding safety risk independent of formulation quality.
Compounded vs. brand: what providers need to see side by side
| Feature | FDA-approved brand (Wegovy / Ozempic / Zepbound / Mounjaro) | Compounded versions |
|---|---|---|
| FDA review for safety & efficacy | Yes — rigorous premarket approval process | No — not reviewed before marketing |
| Active ingredient verified | Yes — semaglutide or tirzepatide as approved | Varies — may contain salt forms (semaglutide sodium/acetate) not equivalent to approved ingredient |
| Dosing format | Pre-filled pen — fixed dose, no measuring required | Multi-dose vial + syringe — patient must measure dose; high error risk |
| Concentration consistency | Standardized — same concentration every pen, every lot | Variable — varies between compounders and sometimes between batches |
| cGMP manufacturing standards | Yes | 503B only — 503A pharmacies not subject to cGMP |
| FDA inspection of manufacturer | Yes | 503B only — 503A pharmacies not FDA-inspected; API source may be uninspected overseas manufacturers |
| Adverse event reporting required | Yes | 503B only — 503A pharmacies not required to report to FDA |
| Clinical trial safety data | Extensive — STEP and SURMOUNT programs, thousands of participants | None — no RCT evidence for compounded formulations |
| Additional ingredients | Known, standardized | Variable — may include B vitamins, L-carnitine, or other APIs not in approved drug; interactions unstudied |
| Legal status (post-May 2025) | Fully legal | Generally prohibited as essentially-copy — narrow patient-specific exceptions only; subject to FDA enforcement |
| Cost (typical) | Self-pay brand options: ~$149–$449/month through programs like TrumpRx, manufacturer savings programs, and telehealth platforms now carrying brand. Insurance-covered with PA: often $0–$50 copay. Note: the $900–$1,400 retail sticker price is largely a non-issue for patients who use savings programs or approved channels. | $150–$500/month — lower cost was the primary driver of patient uptake during the shortage era, but the self-pay brand gap has narrowed considerably in 2026 |
What to tell patients who ask about or are on compounded
Patients on compounded GLP-1 medications during the shortage era fall into several categories: those who knew they were on a compounded version and made an informed choice, those who didn't know they weren't getting brand medication, and those who are still actively seeking compounded options now that the shortage has ended. Each requires a slightly different conversation.
"The compounded version you were on was a legal option during the shortage, and I'm not here to second-guess that decision. Now that the shortage has ended, I want to make sure you're on the FDA-approved medication going forward — both because it's legally the right path and because the approved versions have the safety track record we rely on. Let's get you set up with the brand version and navigate any insurance or cost hurdles together."
"The reason compounding was available was that there wasn't enough of the brand medication to go around. That supply problem has been resolved. Continuing to use a compounded version now isn't just legally complicated for the pharmacy — it means you're on a product that hasn't gone through the same quality and safety review as the brand. The dosing format alone carries real risk; the pre-filled pen format in the approved version removes a whole category of error that we've seen cause hospitalizations."
"Cost is a real and legitimate concern, and I hear you. The brand medication is significantly more expensive out of pocket. Before we decide you can't access it, I want to make sure we've gone through every option: manufacturer savings programs, prior authorization with your insurance, and whether any alternative agents might work for you. Compounded is no longer a legal bridge — but there are other paths we can try before concluding the cost is insurmountable."
"I want to make sure you have complete information. What you were receiving was a compounded version of this medication — not the FDA-approved brand. Compounding was legally permitted during the period you were on it, but there are real differences I want you to understand: the formulation, the dosing method, and the level of quality oversight were different from the brand product. Going forward, I'm going to prescribe the approved version, and here's what that transition looks like."
Patient transition guidance — moving from compounded to brand
The practical challenge for providers is that patients who were stable on compounded doses may not have been on the same dose equivalents as the approved titration schedule. Compounded vials were often prepared at non-standard concentrations, and dosing instructions varied widely between compounding pharmacies and telehealth platforms.
- Ask the patient what dose they were taking and in what units — mg, mL, or "units" — and what concentration their vial was
- Verify what the patient was actually receiving, if possible — dose and concentration are not standardized across compounders
- Do not assume the compounded dose equates directly to a brand titration dose
- Consider restarting at the lowest brand dose and re-escalating, particularly if the patient had GI side effects on compounded
- Check for add-on ingredients in the compounded formulation — note any B vitamins or other APIs that were present
- Patients may experience renewed GI side effects transitioning to brand even if they were tolerating compounded well — formulation differences may contribute
- Dose response may differ — efficacy at equivalent doses is not guaranteed given active ingredient differences in some compounded products
- Insurance PA may be required for brand — document clinical indication, prior treatment history, and medical necessity clearly
- Manufacturer savings programs (Novo Nordisk, Eli Lilly) may substantially reduce cost for eligible patients — check current program eligibility
Documentation and liability considerations
Providers who prescribed compounded GLP-1 medications during the shortage era generally did so legally, and the legal protection afforded by the shortage designation was real. The risk landscape has changed materially now that enforcement discretion has expired. Providers prescribing compounded versions today — or transitioning patients without documentation — face real liability exposure.
🚨 Prescriber liability red flags — do not do these things
- Do not write prescriptions for compounded semaglutide or tirzepatide for cost savings alone — this does not meet the patient-specific clinical need exception and creates prescriber liability
- Do not prescribe through telehealth platforms that are continuing to dispense compounded GLP-1s without evidence of a legal basis for doing so — you are the prescriber of record
- Do not prescribe compounded versions at doses, concentrations, or titration schedules that deviate from approved labeling without documented medical justification — this was a primary driver of adverse events
- Do not ignore patient reports of adverse events experienced on compounded versions — document them and report to MedWatch
- Do not assume that an online telehealth platform's claim that "our compounding is still legal" is accurate without independent verification — litigation and enforcement are active
What comes next — the 503A/503B landscape going forward
The compounding question is not fully settled, and the regulatory and legal landscape will continue to evolve. Here is what is clear, what is unresolved, and what providers should watch for.
- Shortages for both semaglutide and tirzepatide are resolved — survived multiple court challenges
- Bulk compounding of essentially-copy semaglutide and tirzepatide is prohibited and actively enforced — 85+ warning letters issued since September 2025
- FDA has threatened seizure and injunction "without further notice" for non-compliant entities
- Oral semaglutide (Wegovy tablet) is now FDA-approved and available — eliminating the last remaining rationale for compounded oral semaglutide
- Major telehealth platforms (Hims & Hers) are transitioning to brand partnerships — the Novo Nordisk deal may be a model for others
- ADA and AMA have both formally discouraged use of compounded GLP-1s
- FDA API import restrictions — "green list" of approved API manufacturers; import alerts for uninspected sources; further restrictions on which APIs can be used in compounding expected
- The 80% add-on ingredient strategy is under active FDA scrutiny — further guidance on whether B vitamins or other additives constitute a "significant difference" for 503A purposes is expected
- DOJ investigation into Hims & Hers referral — outcome could set precedent for telehealth liability
- Generic semaglutide remains unavailable — cost access gap persists and will drive continued patient demand for lower-cost alternatives
- TrumpRx and similar government-affiliated direct-access programs offering brand GLP-1s at reduced cost (Wegovy tablets ~$149–299/month) may shift the access calculus for some patients
- State-level enforcement varies significantly — some boards of pharmacy actively pursuing compounders; others less engaged
Most patients who accessed compounded GLP-1 medications during the shortage era were not doing anything wrong. They were filling a real prescription for a real clinical indication through a channel that was legally available to them. Many experienced meaningful clinical benefit. The shift in their access situation is a clinical management problem, not a moral failing on their part or yours.
In practice, I approach these transitions as I would any formulary change: acknowledge the disruption, understand the patient's current status clinically, assist with whatever access navigation is needed, and be honest about the limitations of what the brand product can offer in terms of cost without insurance coverage. For patients who truly cannot afford the brand product, the conversation about alternative anti-obesity medications is worth having explicitly — other approved agents exist, some with better formulary access, even if efficacy differs.
If a patient experienced a negative outcome on compounded — a dosing error, a hospitalization, an adverse reaction — document it, report it to MedWatch, and be transparent with the patient about what happened and why. The adverse event data on compounded GLP-1s is substantially underreported. Accurate reporting protects future patients.
References and sources
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Updated March 2025. fda.gov
- FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Updated February 2026. fda.gov
- FDA. Declaratory order: resolution of shortage of tirzepatide injection products. December 19, 2024. FDA declaratory order (PDF)
- FDA. Dosing errors alert — compounded injectable semaglutide products. July 26, 2024. fda.gov
- Alston & Bird. FDA resolves semaglutide shortage: next steps for community pharmacies and providers. March 2025. alston.com
- Harris Beach Murtha. GLP-1 weight-loss drugs off shortage list: deadlines to stop compounding. June 2025. harrisbeachmurtha.com
- University of Illinois Chicago Drug Information Group. What are the safety concerns regarding compounded GLP-1 receptor agonists? August 2025. uic.edu
- National Consumers League. Fraud, counterfeits, and unsafe doses: NCL sounds alarm on compounded GLP-1 market. September 2025. nclnet.org
- National Association of Manufacturers. Compounded drugs threaten patient safety. August 2025. nam.org
- NCPA. FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide. March 2025. ncpa.org
- McDermott Will & Emery. Semaglutide shortage resolved. March 2025. mwe.com
- FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. FDA News Release. March 3, 2026. fda.gov
- Frier Levitt. From crackdown to collaboration: FDA warning letters and the Hims–Novo Nordisk deal signal a new era for compounded GLP-1 drugs. March 2026. frierlevitt.com
- Healthcare Brew. Despite FDA crackdown, unapproved GLP-1s still threaten the industry. March 23, 2026. healthcare-brew.com
- Pharmacy Times. FDA and Novo Nordisk warned of GLP-1 telehealth compounding take down — what's next? March 2026. pharmacytimes.com
- MedShadow Foundation. FDA drug recalls and warnings: recalls for compounded semaglutide and tirzepatide. September 2025. medshadow.org